If they're telling the whole truth then the Phenox MoU isn't progressing because of changes to their business in APAC. It's possible this could morph into a smaller agreement for other locations but unlikely as they didn't mention anything.
Stock is a big problem. They don't have any of the cameras which is their best seller and this will impact revenue for Q3 and likely Q4. They need to get that new stock in ASAP which will lower cash reserves. The next half looks rough and then it's all down to the uptake of the next-gen products and Remedi. On the plus side they have cash and the new marketing plan of announcing products when ready is sensible. What results would you need to see to buy?
BDT Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
